ClinicalTrials.gg
CompletedNCT03196206Updated Jun 10, 2022

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

A Phase 1 interventional study of BMS-986177 in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-10.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Mar 2018, 8 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Thrombosis by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Thrombosis · Bristol-Myers Squibb.

Enrollment
14th of 19
24 · median 42
Started
2017
with 3 others
Phase 1
13 of 19
none open now
Registered
14th of 19
by date

Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 14th largest by enrollment, is one of 4 that started in 2017, is one of 13 in phase 1, and was the 14th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

None of the 19 studies in Thrombosis by Bristol-Myers Squibb is open now. The open studies under Thrombosis, anywhere →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Thrombosis by Bristol-Myers Squibb as a file.
02

Study summary

Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants in Groups B and C will be classified by renal function by eGRF at screening and confirmed on Day -1
  • Participants in Group A will be healthy participants as determined by no significant deviations in normal medical and surgical history and assessments
  • Participants in Group A must have a of 18.0 to 32.0 kg/m2, inclusive
  • Females must be of non-

Exclusion criteria

Exclusion Criteria:

  • Participants in Groups B and C cannot have an indwelling catheter for hemodialysis
  • Participants in Groups B and C cannot have had, nor be waiting for, an organ transplant

Other protocol defined inclusion and exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group A

    Normal Renal Function

    Drug: BMS-986177

  • Experimental
    Group B

    Moderate Renal Impairment

    Drug: BMS-986177

  • Experimental
    Group C

    Severe Renal Impairment

    Drug: BMS-986177

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Measured by plasma concentration

    Time frame: Up to 5 days

  2. AUC from time zero to time of last quantifiable concentration (AUC (0-T))

    Summary measures of PK parameters

    Time frame: Up to 5 days

  3. AUC from time zero extrapolated to infinite time (AUC (INF))

    Summary measures of PK parameters

    Time frame: Up to 5 days

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Safety and tolerability as measured by incidence of AEs

    Time frame: Up to 5 days

  2. Incidence of Serious Adverse Events ( SAEs)

    Safety and tolerability as measured by incidence of SAEs

    Time frame: Up to 30 days

  3. Change from baseline in electrocardiogram findings

    Measured by investigator assessment

    Time frame: Up to 5 days

  4. Change from baseline in physical examination findings

    Measured by investigator assessment

    Time frame: Up to 5 days

  5. Change from baseline in clinical laboratory test findings

    Measured by investigator assessment

    Time frame: Up to 5 days

07

Study locations

3 sites
  • Clinical Pharmacology Of Miami Inc.
    Miami, Florida 33014, United States
  • Clinical Pharmacology of Miami LLC
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

References and documents

Publications

  • Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, Bello A, Murthy B. Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment. Clin Pharmacokinet. 2022 Oct;61(10):1405-1416. doi: 10.1007/s40262-022-01150-1. Epub 2022 Jul 30. PubMed 35906349 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Mar 2018, 7 months.

Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2017
First posted
Jun 22, 2017
StartActual
Jul 13, 2017
Primary completionActual
Mar 4, 2018
CompletionActual
Mar 4, 2018
Last update
Jun 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03196206
Responsible party
Sponsor
First posted
Jun 22, 2017
Start date
Jul 13, 2017
Primary completion
Mar 4, 2018
Completion
Mar 4, 2018
Last update
Jun 10, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion